BRAF and neoplasm: Since then it has been reported that while targeting multiple components of the RAF–MEK–ERK pathway yield initial tumor regression in most patients with BRAF(V600E) mutation, resistance often still occurs (Chatterjee and Bivona, 2019; Yu et al., 2019).